INFARMED
ActiveFrom the official registers: KBO 37 annual accounts at the National Bank publications in the Belgian Official Gazette
Summary
INFARMED has been active since 1989 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €276,783 and a net result of -€9,051. Equity is shrinking by about 2.8% per year across the filed financial years. Its solvency ranks better than 59% of 20,678 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
18-05
financial year 2025 · micro format
2025
31-12
Financial
Weakest financial yearnet -€9,051
Net result drops to -€9,051, the lowest in the series.
18-08
financial year 2024 · micro format · 18 days late
2024
31-12
Financial
Back to profitnet €7,438
Net result €7,438 after one loss-making year.
31-12
Financial
Liquidity more than 12 timescurrent ratio 1.02
Current ratio from 0.08 to 1.02; short-term debt falls from €195,771 to €101,671.
16-07
financial year 2023 · micro format
2023
20-06
financial year 2022 · micro format
2022
31-12
Financial
Back to profitnet €16,703
Net result €16,703 after one loss-making year.
07-07
financial year 2021 · micro format
2021
02-06
financial year 2020 · micro format
2020
10-06
financial year 2019 · micro format
2019
31-12
Financial
Equity above €500,000equity €511,742 ▲6%
A profit in every financial year since 2018 builds equity to €511,742.
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank